ReviewDrugs in context2018
Severe refractory asthma: current treatment options and ongoing research.
Review in Drugs in context, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gender bias in clinical trials of biological agents for severe asthma: A systematic review.PloS one · 2021Pooled it
- Article
- Article
- Interleukin 31 receptor α promotes smooth muscle cell contraction and airway hyperresponsiveness in asthma.Nature communications · 2023Article
- [The profile of severe asthmatics: Results from a specialized asthma clinic].Tuberkuloz ve toraks · 2023Observational
- Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab.Biomedicines · 2021Review
- Asthma and stroke: a narrative review.Asthma research and practice · 2021Review
- A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab.Respiratory medicine case reports · 2021Article
- Uncontrolled Asthma: Unmet Needs in the Management of Patients.Journal of asthma and allergy · 2021Review
- A narrative review of research advances in mesenchymal stem cell therapy for asthma.Annals of translational medicine · 2020Review
- Beliefs and preferences regarding biological treatments for severe asthma.The World Allergy Organization journal · 2020Article
- Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights.Journal of asthma and allergy · 2020Review
- Targeting eosinophils: severe asthma and beyond.Drugs in context · 2019Review
- New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic.Biologics : targets & therapy · 2019Article
- Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?Drugs in context · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with severe asthma have a greater risk of asthma-related symptoms, morbidities, and exacerbations. Moreover, healthcare costs of patients with severe refractory asthma are at least 80% higher than those with stable asthma, mainly because of a higher use of healthcare resources and chronic side effects of oral corticosteroids (OCS). The advent of new promising biologicals provides a unique therapeutic option that could achieve asthma control without OCS. However, the increasing number of available molecules poses a new challenge: the identification and selection of the most appropriate treatment. Thanks to a better understanding of the basic mechanisms of the disease and the use of predictive biomarkers, especially regarding the Th2-high endotype, it is now easier than before to tailor therapy and guide clinicians toward the most suitable therapeutic choice, thus reducing the number of uncontrolled patients and therapeutic failures. In this review, we will discuss the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice. The availability of new molecules, specific for different molecular targets, is a key topic, especially when considering that the same targets are sometimes part of the same phenotype. The aim of this review is to help clarify these doubts, which may facilitate the clinical decision-making process and the achievement of the best possible outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.